TipRanks
Advertisement
Advertisement

PRNAF Stock Latest News

Alterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference
Company AnnouncementsAlterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference
23h ago
Alterity’s ATH434 slowed multiple system atrophy decline 52% in new data
PremiumThe Fly
Alterity’s ATH434 slowed multiple system atrophy decline 52% in new data
5d ago
ATHE
Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial
PremiumCompany Announcements
Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial
5d ago
Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline
PremiumCompany Announcements
Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline
15d ago
Alterity Flags Development Risks Around Lead Neurodegeneration Drug ATH434
PremiumCompany Announcements
Alterity Flags Development Risks Around Lead Neurodegeneration Drug ATH434
17d ago
Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference
PremiumCompany AnnouncementsAlterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference
22d ago
Alterity Therapeutics Seeks Quotation for New ASX Shares
Premium
Company Announcements
Alterity Therapeutics Seeks Quotation for New ASX Shares
24d ago
Alterity Therapeutics management to meet virtually with Lake Street
Premium
The Fly
Alterity Therapeutics management to meet virtually with Lake Street
25d ago
ATHE
Alterity Therapeutics management to meet virtually with Lake Street
PremiumThe Fly
Alterity Therapeutics management to meet virtually with Lake Street
25d ago
ATHE
Alterity Therapeutics initiated with a Buy at Lake Street
PremiumThe Fly
Alterity Therapeutics initiated with a Buy at Lake Street
25d ago
ATHE
Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal
PremiumCompany Announcements
Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal
1M ago
Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares
PremiumCompany Announcements
Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares
1M ago
Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference
PremiumCompany AnnouncementsAlterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference
1M ago
Alterity Therapeutics Updates Director Equity Holdings After Option Expiry
Premium
Company Announcements
Alterity Therapeutics Updates Director Equity Holdings After Option Expiry
1M ago
Alterity Director Peter Marks Converts Options, Lifts Equity Stake
Premium
Company Announcements
Alterity Director Peter Marks Converts Options, Lifts Equity Stake
1M ago
Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares
PremiumCompany Announcements
Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares
1M ago
Alterity Therapeutics Files 2026 Annual Report and XBRL Data with SEC
PremiumCompany Announcements
Alterity Therapeutics Files 2026 Annual Report and XBRL Data with SEC
1M ago
Alterity Taps Underwritten ATHO Options to Fund ATH434 MSA Program
PremiumCompany Announcements
Alterity Taps Underwritten ATHO Options to Fund ATH434 MSA Program
1M ago
Alterity Therapeutics Reaffirmed at Buy as Pivotal Phase 3 Nears; $16 Price Target Maintained
PremiumRatings
Alterity Therapeutics Reaffirmed at Buy as Pivotal Phase 3 Nears; $16 Price Target Maintained
1M ago
ATHE
Alterity Therapeutics Seeks ASX Quotation for 1.7 Million New Shares
PremiumCompany AnnouncementsAlterity Therapeutics Seeks ASX Quotation for 1.7 Million New Shares
1M ago
Alterity Therapeutics Files Updated Corporate Governance Statement with ASX
Premium
Company Announcements
Alterity Therapeutics Files Updated Corporate Governance Statement with ASX
1M ago
Alterity Therapeutics Doubles Annual Loss as It Ramps Up Neurodegeneration R&D
Premium
Company Announcements
Alterity Therapeutics Doubles Annual Loss as It Ramps Up Neurodegeneration R&D
1M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >